FDA approves Schering-Plough's Pegintron to treat paediatric hepatitis C
This article was originally published in Scrip
Executive Summary
The US FDA has granted Schering-Plough's combination therapy of Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) marketing approval for use in previously untreated patients three years and older with chronic hepatitis C (HCV).